Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Operating Leases: 2022-2025

Historic Operating Leases for Fulcrum Therapeutics (FULC) over the last 4 years, with Sep 2025 value amounting to $4.7 million.

  • Fulcrum Therapeutics' Operating Leases fell 33.49% to $4.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.7 million, marking a year-over-year decrease of 33.49%. This contributed to the annual value of $6.4 million for FY2024, which is 25.33% down from last year.
  • According to the latest figures from Q3 2025, Fulcrum Therapeutics' Operating Leases is $4.7 million, which was down 11.65% from $5.3 million recorded in Q2 2025.
  • In the past 5 years, Fulcrum Therapeutics' Operating Leases ranged from a high of $12.8 million in Q1 2022 and a low of $4.7 million during Q3 2025.
  • Over the past 3 years, Fulcrum Therapeutics' median Operating Leases value was $7.6 million (recorded in 2024), while the average stood at $7.5 million.
  • Data for Fulcrum Therapeutics' Operating Leases shows a maximum YoY slumped of 33.49% (in 2025) over the last 5 years.
  • Over the past 4 years, Fulcrum Therapeutics' Operating Leases (Quarterly) stood at $10.8 million in 2022, then declined by 20.26% to $8.6 million in 2023, then dropped by 25.33% to $6.4 million in 2024, then crashed by 33.49% to $4.7 million in 2025.
  • Its Operating Leases stands at $4.7 million for Q3 2025, versus $5.3 million for Q2 2025 and $5.9 million for Q1 2025.